Norharman exacerbates 6-hydroxydopamine-induced Parkinson's disease but cannot establish it alone

Physiology and Pharmacology

Volumn 15, Issue 2, 2011, Pages 260-267

  Haghdoost Yazdi, Hashem ^a   Movahedi, Mohadeseh ^a   Faraji, Ayda ^a   Sophiabadi, Mohamad ^a  

^a QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

6 OHDA; Elevated body swing test; Norharman; Parkinson's disease; Rat

Indexed keywords

APOMORPHINE; BETA CARBOLINE; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; MOUSE; NONHUMAN; PARKINSON DISEASE; EXPERIMENTAL PARKINSONISM; EXPERIMENTAL TEST; RAT;

EID: 80052578033     PISSN: 17350581     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Adell A, Biggs TA, Myers RD, Action of harman 1-methyl-b-carboline on the brain: body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacol 35 (1996) 1101-7.
2. Anderson NJ, Tyacke RJ, Husbands SM, Nutt DJ. Hudson AL, Robinson ESJ, In vitro and ex vivo distribution of [H] harmane, b-carboline, in rat brain. Neuropharmacol 50 (2006) 269-276.
3. Baum SS, Hill R, Rommelspacher H, Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur J Pharmacol 314 (1996) 75-82.
4. Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS, Pesticides and Parkinson's disease--is there a link? Environ Health Perspect. 114 (2) (2006) 156-64.
5. Cesario V, Borlongan CV, Sanberg PR. Elevated Body Swing Test: A New Behavioral Parameter for Rats with 6-Hydroxydopamine-Induced Hemiparkinsonism, J Neuroscience 15 (7) (1995) 5372-5378.
6. Chuang C, Su H, Cheng F, Hsu SH, Chuang CF, Liu CS, Quantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson's disease. J Bio Sci 13 (2010) 17:9.
7. Collins MA, Neafsey EJ, Matsubara K, Cobuzzi RJ Jr, Rollema H,. Indole-Nmethylated-carbolinium ions as potential brain-bioactivated toxins. Brain Res 505 (1992) 154-60.
8. Collins MA, Neafsey EJ. Potential neurotoxic "agents provocateurs" in Parkinson's disease. Neurotoxicol Teratol 24 (2002) 571-7.
9. Dauer W, Przedborski S. Parkinson's Disease: Mechanisms and Models. Neuron 39 (2003) 889-909.
10. Fujita M, Nishino H, Kumazaki M, Shimada S, Tohyama M, Nishimura T. Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Brain Res Mol Brain Res. 39 (1-2) (1996) 127-36.
11. Hamann J, Rommelspacher H, Storch A, Reichmann H, Gille G, Neurotoxic mechanisms of 2,9-dimethyl-bcarbolinium ion in primary dopaminergic culture. J Neurochem 98 (2006) 1185-99.
12. Kim DH, Jang YY, Han ES, Lee CS, Protective effect of harmaline and harmalol against dopamine-and 6-hydroxydopamine-induced oxidative damage of brain mitochondria and synaptosomes, and viability loss of PC12 cells. Eur J Neurosci 13 (2001) 1861-72.
13. Kim HH, Jang YY, Han ES, Lee CS, Differential antioxidant effects of ambroxol, rutin, glutathione and harmaline. J Appl Pharmacol 7 (1999) 112-20.
14. Kuhn W, Müller TH, Grosse H, Rommelspacher H, Elevated levels of Harman and norharman in cerebrospinal fluid of parkinsonian patients. J Neural Transm 103 (1996) 1435-40.
15. Lee CS, Han ES, Jang YY, Han JH, Ha HW, Kim DE, Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells. J Neurochem 75 (2000) 521-31.
16. Loew GH, Nienow J, Lawson JA, Toll L, Uyeno ET, Theoretical structure-activity studies of b-carboline analogs. Requirements for benzodiazepine receptor affinity and antagonist activity. Mol Pharmacol 28 (1985) 17-31.
17. Maher P, Davis JB, The role of monoamine metabolism in oxidative glutamate toxicity. Neuroscience 16 (1996) 6394-401.
18. Matsubara K, Aoyama K, Suno M, Awaya T, Nmethylation underlying Parkinson's disease. Neurotoxicol Teratol 24 (2002) 593-8.
19. Matsubara K, Gonda T, Sawada H, Uezono T, Kobayashi Y, Kawamura T, Ohtaki K, Kimura K, Akaike A, Endogenously occurring b-carboline induces parkinsonism in nonprimate animals: A possible causative protoxin in idiopathic Parkinson's disease. J Neurochem 70 (1998) 727-35.
20. Nagatsu T, Amine-related neurotoxins in Parkinson's disease past, present, and future. Neurotoxicology Teratology 24 (2002) 565-569.
21. Pavlovic S, Schulze G, Wernicke C, Bonnet R, Gille G, Badiali L, Kaminska A, Lorenc-Koci E, Ossowska K, Rommelspacher H, 2,9-Dimethyl-b-carbolinium, a neurotoxin occuring in human brain, is an equipotent apoptotic inducer as 1-methyl-4-phenylpyridinium (MPP+). Neuroscience 139 (2006) 1525-37.
22. Paxinos G, Watson C, The rat brain in stereotaxic coordinates. 6th ed. San Diego, CA: Academic Press; 2007.
23. Shi CC, Chen SY, Wang GJ, Liao JF, Chen CF, Vasorelaxant effect of harman. Eur J Pharmacol 390 (2000) 319-25.
24. Shimohama S, Sawada H, Kitamura Y, Taniguchi T, Disease model: Parkinson's Disease. Trends Mol Med 9 (2003) 360-365.
25. Tse SYH, Mak IT, Dickens BF, Antioxidative properties of harmane and bcarboline alkaloids. Biochem Pharmacol 42 (1991) 459-64.
26. Tsuchiya H, Yamada K, Ohtani S, Takagi N, Todoriki H, Hayashi T, Determination of tetrahydro--carbolines in rat brain by gas chromatography-negative-ion chemical ionization mass spectrometry without interference from artifactual formation. J of Neuroscience Methods, 62 (1) (1995) 37-41.